Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, HoldingsChannel reports. The fund bought 318 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.
Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC raised its position in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Wellington Management Group LLP increased its stake in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after purchasing an additional 1,793,145 shares during the period. International Assets Investment Management LLC lifted its stake in Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Finally, Pacer Advisors Inc. grew its holdings in Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after purchasing an additional 1,564,792 shares during the period. Institutional investors own 83.67% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on GILD shares. Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Finally, Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.96.
Insiders Place Their Bets
In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 over the last quarter. 0.29% of the stock is owned by corporate insiders.
Gilead Sciences Stock Performance
Gilead Sciences stock opened at $91.84 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The firm’s fifty day moving average price is $91.85 and its 200-day moving average price is $83.81.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s payout ratio is 3,422.22%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- Want to Profit on the Downtrend? Downtrends, Explained.
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Stock Market Sectors: What Are They and How Many Are There?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.